| Bioactivity | Anivamersen sodium is an RNA aptamer to reverse the anticoagulant effect of the parenteral factor IXa inhibitor pegnivacogin. REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary sequence reversal oligonucleotide. |
| Name | Anivamersen sodium |
| CAS | 959716-31-5 |
| Formula | C157H194N56Na14O103P14 |
| Molar Mass | 5269.10 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lincoff AM, Mehran R, Povsic TJ, et al. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial [published correction appears in Lancet. 2016 Mar 19;387(10024):1162. Boudoulas, Dean [corrected to Boudoulas, Konstantinos D.]]. Lancet. 2016;387(10016):349-356. doi:10.1016/S0140-6736(15)00515-2 |
Anivamersen sodium
CAS: 959716-31-5 F: C157H194N56Na14O103P14 W: 5269.10
Anivamersen sodium is an RNA aptamer to reverse the anticoagulant effect of the parenteral factor IXa inhibitor pegnivac
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.